First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignanciesSandra Irenaeus, Gustav Ullenhag, Peter Ellmark et al.|International Journal of Cancer|2019Cited by 142
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1Karin Enell Smith, Peter Ellmark|Cancer Immunology Immunotherapy|2023Cited by 8